Sirona Biochem Corp V.SBM

Alternate Symbol(s): SRBCF

Healthcare Biotechnology

Sirona Biochem Corp. is a cosmetic ingredient and drug discovery company with a proprietary technology platform developed at its laboratory facility in France with a specialization in the stabilization of carbohydrate molecules. The Company is exploring the areas of diabetes, dyschromia, anti-aging, anti-cellulite and antiviral therapies and relies on a business model of licensing patents to large organizations in return for up-front and milestone payments as well as royalties. Its two most advanced programs are the cosmetic skin lightener and diabetes drug. The Company's TFC-1067 is for the treatment of Dyschromia (Dark spots on the skin). GlycoProteMim is a novel anti-aging compound. GlycoProteMim is based on the naturally occurring glycoproteins found in Antarctic fish, known to protect them against environmental stressors. It is focused on three current antiviral categories: Neuraminidase Inhibitors, Nucleoside Analogs and Iminosugars. Its wholly owned subsidiary is TFChem S.A.R.L.

TSXV:SBM - Post by User

Sirona Biochem Corp

Bullboard Posts

Comment by tickle1ston Nov 10, 2015 1:18pm

85 Views

Post# 24277752

RE:RE:RE:RE:RE:RE:Bloomberg link to Franfurt/Sirona

radared...that's what I've been saying. When the SBM story gets past the Vancouver promo tarnish that comes with the Van exchange, delivers believable news on pipline deals instead of fluffy pump and dump cr.ap when SBM stops printing cheap paper at every turn (because they can), the shares stop churning and churning, the real institutional investors will come to the dance, drive the price up, hold shares and create shareholder value.

Acoording to the new pig, he thinks this might happen in a couple a months...if i read the anouncement right.

Bullboard Posts

Invest wiser with BMO's InvestorLine Platform features